Quick Answer
Ovid Therapeutics Inc. reported Stockholders Equity of $130.66 million for the year ending 2025.
- Ovid Therapeutics Inc. showed an increase of +91.5% in Stockholders Equity from 2024 to 2025.
- This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $42.34 million | Q2 2017: $100.94 million | Q3 2017: $92.96 million | Q1 2018: $72.09 million | Q2 2018: $61.12 million | Q3 2018: $49.97 million | Q1 2019: $57.25 million | Q2 2019: $45.44 million | Q3 2019: $30.05 million | Q1 2020: $51.44 million | Q2 2020: $30.48 million | Q3 2020: $63.64 million | Q1 2021: $221.11 million | Q2 2021: $206.71 million | Q3 2021: $197.02 million | Q1 2022: $165.00 million | Q2 2022: $152.15 million | Q3 2022: $142.05 million | Q1 2023: $120.95 million | Q2 2023: $110.70 million | Q3 2023: $101.29 million | Q1 2024: $78.28 million | Q2 2024: $88.90 million | Q3 2024: $76.29 million | Q1 2025: $59.28 million | Q2 2025: $55.79 million | Q3 2025: $44.70 million.
- Over the full 12 years of available data (2014 to 2025), Ovid Therapeutics Inc.'s Stockholders Equity has grown by 2,657.6%.
- Historical annual values: Fiscal year 2025: $130.66 million | Fiscal year 2024: $68.23 million | Fiscal year 2023: $87.80 million | Fiscal year 2022: $132.27 million | Fiscal year 2021: $179.75 million | Fiscal year 2020: $43.63 million | Fiscal year 2019: $70.02 million | Fiscal year 2018: $38.81 million | Fiscal year 2017: $83.44 million | Fiscal year 2016: $49.29 million | Fiscal year 2015: $68.07 million | Fiscal year 2014: $4.74 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: